Code XG003

HEPA-IC

ELISA Kit for the detection of Squamous Cell Carcinoma Antigen (SCCA) variants Immune Complexes in Hepatocellular Carcinoma (HCC)

An ELISA assay for Hepatocellular Carcinoma (HCC) detection in patient sera. Published studies have shown that Hepa-IC has a 70% sensitivity rate and a 100% specificity over healthy controls. These figures are much higher than the gold standard serological marker for HCC, Alpha fetoprotein (AFP). Hepa-IC can be used to evaluate the progress of HCC development in cirrhotic patients and can be used to monitor chronic hepatitis patients, thus increasing the application of Hepa-IC to an even larger patient population. In addition, Hepa-IC has demonstrated the ability to evaluate chronic hepatitis patients' response to interferon and lavimudine therapies.

Hepa-IC allows the diagnosis of HCC in the early stages of development, the possibility to monitor at risk populations such as chronic hepatitis and cirrhotic patients and the ability to evaluate patients response to therapies.